Cerevel Therapeutics is dedicated to advancing the treatment of neuroscience diseases by focusing on the underlying neurocircuitry that drives symptoms. The company employs a scientific strategy that leverages recent advancements in chemistry, genomics, and proteomics to enhance the understanding of neural networks. This approach allows for the development of highly specific therapeutic candidates aimed at addressing the unique challenges posed by various neuroscience diseases. By utilizing techniques such as allosteric modulation, Cerevel aims to fine-tune neural network functions, optimizing therapeutic benefits while minimizing unwanted side effects.

The company is advancing a diverse pipeline of small molecule therapies designed to meet significant unmet medical needs in the field of neuroscience. Their pipeline includes multiple preclinical and clinical-stage candidates targeting conditions such as schizophrenia, epilepsy, and Parkinson's disease. Each therapeutic candidate is developed with a focus on achieving optimal efficacy and safety, addressing the limitations of existing treatments. Cerevel's commitment to innovation in neuroscience is evident in their rigorous evaluation processes and their goal of delivering meaningful change for patients affected by these devastating disorders.

United States

Cerevel Therapeutics is working relentlessly to find paths through complexity in an effort to bring real progress and new treatment options to people living with a broad range of neuroscience diseases. On August 1, 2024, AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel's common stock will cease to trade on the NASDAQ stock exchange prior to market open on August 1, 2024. This acquisition is expected to be accretive to adjusted diluted earnings per share (EPS) beginning in 2030.

Cerevel Therapeutics

Company Details